

Please type a plus sign (+) inside this box → ☐

RPTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/622,313
Filing Date	July 17, 2003
First Named Inventor	Barden
Group Art Unit	1645
Examiner Name	Unassigned
Attorney Docket Number	080404-000000US

Total Number of Pages in This Submission

5

ENCLOSURES (check all that apply)

- | | | |
|--|--|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment / Response
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
1) Return receipt postcard
2) Nine (9) references
2) INTERNATIONAL SEARCH REPORT |
|--|--|--|

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

Total number of pages does not include cited references.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm and Individual name

Townsend and Townsend and Crew LLP
Joe Liebeschuetz

Reg No. 37,505

Signature

Date

April 25, 2006

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date:

April 22, 2006

Typed or printed name

Christopher R. Fitting

Signature

Date

April 22, 2006

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60757984

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


PATENT
Attorney Docket No.: 080404-000000US
Client Reference No.: 12627 / KC/nc

On

5/22/06

TOWNSEND and TOWNSEND and CREW LLP

By:



Cl *7/11*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Julian Alexander Barden et al.

Application No.: 10/622,313

Filed: July 17, 2003

For: ANTIBODIES TO NON-
FUNCTIONAL P2X7 RECEPTOR
DIAGNOSIS AND TREATMENT OF
CANCERS AND OTHER CONDITIONS

Confirmation No.: 4347

Examiner: Unassigned

Art Unit: 1645

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references should have been provided to the USPTO pursuant to the sharing agreement between WIPO and the USPTO since the subject application is a US national phase of international application PCT/AU02/00061 and the references have all been cited therein. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Also enclosed is a copy of the International Search Report for the corresponding PCT application.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf
60757923 v1



(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	10/622,313
--------------------	------------

Filing Date	July 17, 2003
-------------	---------------

First Named Inventor	BARDEN, Julian Alexander
----------------------	--------------------------

Art Unit	1645
----------	------

Examiner Name	Unassigned
---------------	------------

Attorney Docket Number	080404-000000US
------------------------	-----------------

[illegible][illegible]

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60757923 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/622,313
				Filing Date	July 17, 2003
				First Named Inventor	BARDEN, Julian Alexander
				Art Unit	1645
				Examiner Name	Unassigned
Sheet	2	of	2	Attorney Docket Number	080404-000000US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AB	BUELL et al., "Blockade of human P2X ₇ receptor function with a monoclonal antibody," <u>Blood</u> , 92(10):3521-3528 (1998).	<input type="checkbox"/>	✓
	AC	FERRARI et al., "ATP-mediated cytotoxicity in microglial cells," <u>Neuropharmacology</u> , 36(9):1295-1301 (1997).	<input type="checkbox"/>	
	AD	GROSCHER-STEWART et al., "Localisation of P2X ₅ and P2X ₇ receptors by immunohistochemistry in rat stratified squamous epithelia," <u>Cell Tissue Research</u> , 296(3):599-605 (1999).	<input type="checkbox"/>	
	AE	GU et al., "A Glu-496 to ala Polymorphism leads to loss of function of the human P2X ₇ receptor," <u>J. Biol. Chem.</u> , 276:11135-11142 (2001).	<input type="checkbox"/>	
	AF	IP et al., "Dynamics of P2X ₇ receptor pore dilation: pharmacological and functional consequences," <u>Drug Dev. Res.</u> , 53(2/3):60-65 (2001).	<input type="checkbox"/>	
	AG	PENG et al., "P2Z purinoceptor, a special receptor for apoptosis induced by ATP in human leukemic lymphocytes," <u>Chinese Medical Journal</u> , 112(4):356-362 (1999).	<input type="checkbox"/>	
	AH	VIRGILIO et al., "Purinergic P2X ₇ receptor: a pivotal role in inflammation and immunomodulation," <u>Drug Dev. Res.</u> , 45(3/4):207-213 (1998).	<input type="checkbox"/>	
	AI	WILEY et al., "Genetic polymorphisms of the human P2X ₇ receptor and relationship to function," <u>Drug. Dev. Res.</u> , 53(2/3):72-76 (2001).	<input type="checkbox"/>	
	AJ	WILEY et al., "A single nucleotide polymorphism is associated with loss of function of the monocyte P2X ₇ receptor," <u>Blood</u> , 96(11 pt 1):abstract 17a (2000).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.